DNA Repair in Prostate Cancer: Biology and Clinical Implications

Lorente, 2015, Sequencing of agents in castration-resistant prostate cancer, Lancet Oncol, 16, e279, 10.1016/S1470-2045(15)70033-1 Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, 783, 10.1056/NEJM200103153441101 Flaherty, 2012, Improved survival with MEK inhibition in BRAF-mutated melanoma, N Engl J Med, 367, 107, 10.1056/NEJMoa1203421 Rubin, 2015, Genomic correlates to the newly proposed grading prognostic groups for prostate cancer, Eur Urol, 69, 2 Baca, 2013, Punctuated evolution of prostate cancer genomes, Cell, 153, 666, 10.1016/j.cell.2013.03.021 Barbieri, 2012, Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer, Nat Genet, 44, 685, 10.1038/ng.2279 Berger, 2011, The genomic complexity of primary human prostate cancer, Nature, 470, 214, 10.1038/nature09744 Abeshouse, 2015, The molecular taxonomy of primary prostate cancer, Cell, 163, 1011, 10.1016/j.cell.2015.10.025 Meeks, 2016, BRCA2 polymorphic stop codon K3326X and the risk of breast, prostate, and ovarian cancers, J Natl Cancer Inst, 108, 10.1093/jnci/djv315 Beltran, 2013, Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity, Eur Urol, 63, 920, 10.1016/j.eururo.2012.08.053 Grasso, 2012, The mutational landscape of lethal castration-resistant prostate cancer, Nature, 487, 239, 10.1038/nature11125 Robinson, 2015, Integrative clinical genomics of advanced prostate cancer, Cell, 161, 1215, 10.1016/j.cell.2015.05.001 Kumar, 2016, Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer, Nat Med, 22, 369, 10.1038/nm.4053 Beltran, 2016, Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer, Nat Med, 22, 298, 10.1038/nm.4045 Gundem, 2015, The evolutionary history of lethal metastatic prostate cancer, Nature, 520, 353, 10.1038/nature14347 Wood, 2011, Human DNA repair genes, Science, 1284, 241 Saleh-Gohari, 2005, Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks, Mol Cell Biol, 25, 7158, 10.1128/MCB.25.16.7158-7169.2005 Goodwin, 2013, A hormone-DNA repair circuit governs the response to genotoxic insult, Cancer Discov, 3, 1254, 10.1158/2159-8290.CD-13-0108 Polkinghorn, 2013, Androgen receptor signaling regulates DNA repair in prostate cancers, Cancer Discov, 3, 1245, 10.1158/2159-8290.CD-13-0172 Lin, 2009, Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer, Cell, 139, 1069, 10.1016/j.cell.2009.11.030 Ju, 2006, A topoisomerase IIβ-mediated dsDNA break required for regulated transcription, Science, 312, 1798, 10.1126/science.1127196 Wu, 2012, Poly-gene fusion transcripts and chromothripsis in prostate cancer, Genes Chromosomes Cancer, 51, 1144, 10.1002/gcc.21999 Tomlins, 2005, Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer, Science, 310, 644, 10.1126/science.1117679 Mani, 2010, Induced chromosomal proximity and the genesis of gene fusions in prostate cancer, Science, 326, 2009 Boysen, 2015, SPOP mutation leads to genomic instability in prostate cancer, Elife, 4, e09207, 10.7554/eLife.09207 Pritchard, 2014, Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer, Nat Commun, 5, 4988, 10.1038/ncomms5988 Chen, 2001, Defects of DNA mismatch repair in human prostate cancer, Cancer Res, 61, 4112 Decker, 2016, Biallelic BRCA2 mutations shape the somatic mutational landscape of aggressive prostate tumors, Am J Hum Genet, 98, 1, 10.1016/j.ajhg.2016.03.003 Castro, 2015, High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers, Ann Oncol, 26, 2293, 10.1093/annonc/mdv356 Carter, 1992, Mendelian inheritance of familial prostate cancer, Proc Natl Acad Sci U S A, 89, 3367, 10.1073/pnas.89.8.3367 Kote-Jarai, 2011, BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients, Br J Cancer, 105, 1230, 10.1038/bjc.2011.383 Leongamornlert, 2012, Germline BRCA1 mutations increase prostate cancer risk, Br J Cancer, 106, 1697, 10.1038/bjc.2012.146 Eeles, 2014, The genetic epidemiology of prostate cancer and its clinical implications, Nat Rev Urol, 11, 18, 10.1038/nrurol.2013.266 Pritchard, 2016, Inherited DNA repair gene mutations in men with metastatic prostate cancer, N Engl J Med, 375, 443, 10.1056/NEJMoa1603144 Bancroft, 2014, Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study, Eur Urol, 66, 489, 10.1016/j.eururo.2014.01.003 Haraldsdottir, 2014, Prostate cancer incidence in males with Lynch syndrome, Genet Med, 16, 553, 10.1038/gim.2013.193 Castro, 2013, Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer, J Clin Oncol, 31, 1748, 10.1200/JCO.2012.43.1882 Castro, 2015, Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer, Eur Urol, 68, 186, 10.1016/j.eururo.2014.10.022 Gallagher, 2012, Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer, BJU Int, 109, 713, 10.1111/j.1464-410X.2011.10292.x Gallagher, 2010, Germline BRCA mutations denote a clinicopathologic subset of prostate cancer, Clin Cancer Res, 16, 2115, 10.1158/1078-0432.CCR-09-2871 Dobzhansky, 1946, Genetics of natural populations. Xiii. Recombination and variability in populations of Drosophila pseudoobscura, Genetics, 31, 269, 10.1093/genetics/31.3.269 Farmer, 2005, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, 434, 917, 10.1038/nature03445 Bryant, 2005, Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase, Nature, 434, 913, 10.1038/nature03443 McCabe, 2006, Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition, Cancer Res, 66, 8109, 10.1158/0008-5472.CAN-06-0140 Murai, 2014, Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib, Mol Cancer Ther, 13, 433, 10.1158/1535-7163.MCT-13-0803 Patel, 2011, Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells, Proc Natl Acad Sci U S A, 108, 3406, 10.1073/pnas.1013715108 Bryant, 2009, PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination, EMBO J, 28, 2601, 10.1038/emboj.2009.206 Murai, 2012, Trapping of PARP1 and PARP2 by clinical PARP inhibitors, Cancer Res., 72, 5588, 10.1158/0008-5472.CAN-12-2753 Schiewer, 2012, Dual roles of PARP-1 promote cancer growth and progression, Cancer Discov, 2, 1134, 10.1158/2159-8290.CD-12-0120 Brenner, 2011, Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer, Cancer Cell, 19, 664, 10.1016/j.ccr.2011.04.010 Kumar, 2010, Nuclear phosphoinositide 3-kinase controls double-strand break DNA repair, Proc Natl Acad Sci U S A, 107, 7491, 10.1073/pnas.0914242107 McCabe, 2015, Mechanistic rationale to target PTEN-deficient tumor cells with inhibitors of the DNA damage response kinase ATM, Cancer Res, 75, 2159, 10.1158/0008-5472.CAN-14-3502 Hussain, 2016, Co-targeting androgen receptor (AR) and DNA repair: a randomized ETS gene fusion-stratified trial of abiraterone + prednisone (Abi) +/− the PARP1 inhibitor veliparib for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) (NCI9012), J Clin Oncol, 34, 5010, 10.1200/JCO.2016.34.15_suppl.5010 Sandhu, 2013, The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial, Lancet Oncol, 2045, 1 Fong, 2009, Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers, N Engl J Med, 361, 123, 10.1056/NEJMoa0900212 Ledermann, 2012, Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer, N Engl J Med, 366, 1382, 10.1056/NEJMoa1105535 Tutt, 2010, Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial, Lancet, 376, 235, 10.1016/S0140-6736(10)60892-6 Ledermann, 2014, Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial, Lancet Oncol, 15, 852, 10.1016/S1470-2045(14)70228-1 Audeh, 2010, Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial, Lancet, 376, 245, 10.1016/S0140-6736(10)60893-8 Kaufman, 2015, Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation, J Clin Oncol, 33, 244, 10.1200/JCO.2014.56.2728 Fong, 2010, Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval, J Clin Oncol, 28, 2512, 10.1200/JCO.2009.26.9589 Shen, 2013, BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency, Clin Cancer Res., 19, 5003, 10.1158/1078-0432.CCR-13-1391 de Bono, 2013, First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors, J Clin Oncol, 31, 2580, 10.1200/jco.2013.31.15_suppl.2580 Ihnen, 2013, Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer, Mol Cancer Ther, 12, 1002, 10.1158/1535-7163.MCT-12-0813 Hussain, 2014, Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer, Invest New Drugs, 32, 904, 10.1007/s10637-014-0099-0 Mateo, 2015, DNA-repair defects and olaparib in metastatic prostate cancer, N Engl J Med, 373, 1697, 10.1056/NEJMoa1506859 Mateo, 2016, An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib, Target Oncol, 11, 401, 10.1007/s11523-016-0435-8 Chao, 2014, Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP, Mol Cancer Res, 12, 1755, 10.1158/1541-7786.MCR-14-0173 Sternberg, 2009, Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial, J Clin Oncol, 27, 5431, 10.1200/JCO.2008.20.1228 Cheng, 2016, Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer, Eur Urol, 69, 992, 10.1016/j.eururo.2015.11.022 Ang, 2013, Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of poly(ADP-ribose) polymerase inhibitor resistance: a multi-institutional study, Clin Cancer Res, 44, 1 Ceccaldi, 2015, A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance, Cancer Res, 75, 1, 10.1158/0008-5472.CAN-14-2593 Aparicio, 2013, Platinum-based chemotherapy for variant castrate-resistant prostate cancer, Clin Cancer Res, 19, 3621, 10.1158/1078-0432.CCR-12-3791